Clinical Validation of an Immunocytochemistry Method Using MARS1

Sponsor
Gangnam Severance Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04759794
Collaborator
(none)
200
5
1
23.4
40
1.7

Study Details

Study Description

Brief Summary

The sensitivity of brushing cytology used to distinguish the cause of biliary strictures is low and clinical usefulness is not secured. The aim of this study was to validate the clinical usefulness of a new differential staining method for cytology which is difficult to differentiate by the conventional staining method using biliary cancer-related protein expressed only in bile duct cancer.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Cytology staining
N/A

Detailed Description

Hypothesis: The statistical significance of new staining method using aminoacyl-tRNA synthetases (ARSs) group in normal bile duct cells and the bile duct cancer cells collected by endoscopic retrograde pancreaticoduodenoscopy (ERCP) will be compared to prove the usefulness of the new staining method.

Clinical study design: The bile duct cytology will be obtained by brushing cytology using ERCP in patients with biliary stenosis. The expression of ARSs in the brushing cytology will be evaluated by a new staining method and compare with the results of the conventional cytology staining method including Papanicolaou staining. Immunofluorescence or immunocytochemistry staining will be performed to differentiate the presence of the tumor. The sensitivity and specificity of the new staining method will be compared with the conventional staining method and its usefulness be confirmed.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
The conventional staining method and new staining method will be performed in cytology specimens obtained from the same patient.The conventional staining method and new staining method will be performed in cytology specimens obtained from the same patient.
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Clinical Validation of an Immunocytochemistry Method Using Antibody of Methionyl-tRNA Synthetase (MARS1) in the Bile Duct Cancer Cell; Multicenter Study
Actual Study Start Date :
Feb 4, 2021
Anticipated Primary Completion Date :
Jan 17, 2023
Anticipated Study Completion Date :
Jan 17, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Bile duct stenosis

This arm includes patients with bile duct stenosis. Endobiliary brushing cytology specimens will be obtained with endoscopic retrograde cholangiopancreatography (ERCP) of patients with bile duct stenosis. Cytology staining will be performed in the cytology specimens.

Diagnostic Test: Cytology staining
Two stainings will be performed in cytology specimens obtained from the same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography conventional cytology staining method new cytology staining method using the antibody of aminoacyl-tRNA synthetases

Outcome Measures

Primary Outcome Measures

  1. The usefulness of new staining method [1 year]

    The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of new staining method will be compared with th conventional Pap staining of brushing cytology specimens.

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with biliary cancer confirmed by imaging (CT, MRI, positron emission tomography)

  • Patients with bile duct cancer diagnosed using brushing cytology by endoscopic retrograde pancreaticoduodenoscopy

  • Patients who underwent surgical treatment with biliary cancer

  • Patients with bile duct stenosis

Exclusion Criteria:
  • Minors under the age of 19, vulnerable subjects such as illiteracy

  • Necrotic specimens

  • Samples with non-diagnostic cytology results and insufficient cells for further evaluation

  • Samples classified as neoplastic (benign or other)

  • Patient with cholangitis in the bile duct

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHA Bundang Medical Center Seongnam Bundang-gu Korea, Republic of 13496
2 Gangnam Severance Hospital Seoul Gangnam-gu Korea, Republic of 06229
3 In Ha University Hospital Incheon Jung-gu Korea, Republic of 22332
4 Soon Chun Hyang University Hospital, Cheonan Cheonan Namdong-gu Korea, Republic of 31151
5 Pusan National University Hospital Busan-si Seo-gu Korea, Republic of 49241

Sponsors and Collaborators

  • Gangnam Severance Hospital

Investigators

  • Study Chair: Sung Ill Jang, MD, PhD, Institutional Review Board, Gangnam Severance Hospital Yonsei University College of Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sung III Jang, Associate professor, Gangnam Severance Hospital
ClinicalTrials.gov Identifier:
NCT04759794
Other Study ID Numbers:
  • 3-2020-0514
First Posted:
Feb 18, 2021
Last Update Posted:
Aug 3, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Sung III Jang, Associate professor, Gangnam Severance Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 3, 2022